Tezepitide Is a GLP1 Imitator

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Eli Lilly plans to apply for the drug to be approved, pending results from a second phase 3 trial wrapping up in April 2023. The levels of weight loss following Tezepitide treatment approach those typically achievable only through bariatric surgery. This procedure reduces body weight by 30% or more after 6 months, and the weight loss continues for the next year or two.

A new generation of anti-obesity medications are displaying striking results: drastically diminishing weight, without the serious side effects of previous medications.

These drugs have raised hopes the weight can be pharmacologically altered in a safe way, but some researchers are concerned about the drugs' high cost, and that these medications could feed into some societies' obsessions with thinness.

This is an audio version of our Feature: The ‘breakthrough’ obesity drugs that have stunned researchers

Hosted on Acast. See acast.com/privacy for more information.